{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:48:47Z","timestamp":1789940927592,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1177\/2168479017741112","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T03:09:06Z","timestamp":1515467346000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance"],"prefix":"10.1007","volume":"52","author":[{"given":"Rima","family":"Izem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Sanchez-Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,30]]},"reference":[{"key":"5202159_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/CVM-2-5-205","volume":"2","author":"CD Furberg","year":"2001","unstructured":"Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2:205\u2013207.","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"5202159_CR2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","volume":"346","author":"JA Staffa","year":"2002","unstructured":"Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539\u2013540.","journal-title":"N Engl J Med"},{"key":"5202159_CR3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"H Duggirala","year":"2016","unstructured":"Duggirala H, Tonning JM, Smith E, et al. Data mining at the food and drug administration. J Am Med Inform Assoc. 2016;23:428\u2013434.","journal-title":"J Am Med Inform Assoc"},{"key":"5202159_CR4","unstructured":"Food and Drug Administration. FDA-FAERS\u2014quarterly report. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082196.htm#QuarterlyReports. Accessed April 2017."},{"key":"5202159_CR5","unstructured":"Health and Human Services. VAERS Data. https:\/\/vaers.hhs.gov\/data\/data. Accessed April 2017."},{"key":"5202159_CR6","unstructured":"Medical Dictionary for Regulatory Activities. MedDRA home page. https:\/\/www.meddra.org\/. Accessed April 2017."},{"key":"5202159_CR7","unstructured":"Food and Drug Administration. Food and Drug Administration\u2014individual case safety reports. https:\/\/www.fda.gov\/ForIndustry\/DataStandards\/IndividualCaseSafetyReports\/default.htm. Accessed April 2017."},{"key":"5202159_CR8","unstructured":"Food and Drug Administration. OpenFDA public website. https:\/\/open.fda.gov\/research\/. Accessed April 2017."},{"key":"5202159_CR9","unstructured":"Food and Drug Administration. FDA, post-market drug and biologic evaluation. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/ucm204091.htm. Accessed April 2017."},{"key":"5202159_CR10","unstructured":"Food and Drug Administration. FDA post-market safety information for patients and providers. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/default.htm. Accessed April 2017."},{"key":"5202159_CR11","unstructured":"European Medicines Agency. EudraVigilance. http:\/\/www.ema.europa.eu\/ema\/index.jsp?%20curl=pages\/regulation\/general\/general_content_000679.jsp&mid=WC0b01ac05800250b5. Accessed April 2017."},{"key":"5202159_CR12","unstructured":"European Center for Disease Prevention and Control. Vaccine adverse event surveillance and communication. http:\/\/vaesco.net\/vaesco.html. Accessed April 2017."},{"key":"5202159_CR13","unstructured":"World Health Organization. WHO: VigiBase. https:\/\/www.who-umc.org\/vigibase\/vigibase\/. Accessed April 2017."},{"key":"5202159_CR14","volume-title":"Public Workshop: The Sentinel Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System","author":"FoodDrug Administration.","year":"2016","unstructured":"Food and Drug Administration. Public Workshop: The Sentinel Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System. Silver Spring, MD: US FDA; 2016."},{"key":"5202159_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1541-0420.00039","volume":"59","author":"M Kulldorff","year":"2003","unstructured":"Kulldorff M, Fang ZX, Walsh SJ. A tree-based scan statistic for database disease surveillance. Biometrics. 2003;59:323\u2013331.","journal-title":"Biometrics"},{"key":"5202159_CR16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","volume":"36","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Trifir\u00f2 G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36:183\u2013197.","journal-title":"Drug Saf"},{"key":"5202159_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/17512433.2015.992878","volume":"8","author":"VK Patadia","year":"2015","unstructured":"Patadia VK, Coloma P, Schuemie MJ, et al.; EU-ADR consortium. Using real-world healthcare data for pharmacovigilance signal detection\u2014the experience of the EU-ADR project. Expert Rev Clin Pharmacol. 2015;8:95\u2013102.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5202159_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/MLR.0b013e31825f63bf","volume":"50","author":"MJ Schuemie","year":"2012","unstructured":"Schuemie MJ, Coloma PM, Straatman H, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50:890\u2013897.","journal-title":"Med Care"},{"key":"5202159_CR19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u2013486.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u2013523.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u2013321.","journal-title":"Eur J Clin Pharmacol"},{"key":"5202159_CR22","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1198\/jasa.2011.ap10243","volume":"106","author":"L Huang","year":"2011","unstructured":"Huang L, Zalkikar J, Tiwari RC. A likelihood ratio test based method for signal detection with application to FDA\u2019s drug safety data. J Am Stat Assoc. 2011;106:1230\u20131241.","journal-title":"J Am Stat Assoc"},{"key":"5202159_CR23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/10543406.2013.736810","volume":"23","author":"L Huang","year":"2013","unstructured":"Huang L, Zalkikar J, Tiwari RC. Likelihood ratio test-based method for signal detection in drug classes using FDA\u2019s AERS database. J Biopharm Stat. 2013;23:178\u2013200.","journal-title":"J Biopharm Stat"},{"key":"5202159_CR24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/0962280214549590","volume":"26","author":"L Huang","year":"2017","unstructured":"Huang L, Zheng D, Zalkikar J, Tiwari R, et al. Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection. Stat Methods Med Res. 2017;26:471\u2013488.","journal-title":"Stat Methods Med Res"},{"key":"5202159_CR25","doi-asserted-by":"crossref","unstructured":"Zhao Y, Yi M, Tiwari RC. Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA\u2019s adverse event reporting system database [published online ahead of print]. Stat Methods Med Res. 2016 May 2.","DOI":"10.1177\/0962280216646678"},{"key":"5202159_CR26","unstructured":"Nam K, Henderson NC2, Rohan P3, Woo EJ3, Russek-Cohen E. Logistic regression likelihood ratio test analysis for detecting signals of adverse events in post-market safety surveillance. J Biopharm Stat. 2017:1\u201319."},{"key":"5202159_CR27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623\u2013625.","journal-title":"Drug Saf"},{"key":"5202159_CR28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-7843.2006.pto_232.x","volume":"98","author":"A Bate","year":"2006","unstructured":"Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol. 2006;98:324\u2013330.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"5202159_CR29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u2013436.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","volume":"25","author":"A Bate","year":"2002","unstructured":"Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25:393\u2013397.","journal-title":"Drug Saf"},{"key":"5202159_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1142\/S0129065705000219","volume":"15","author":"R Orre","year":"2005","unstructured":"Orre R, Bate A, Nor\u00e9n GN, Swahn E, Arnborg S, Edwards IR. A Bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst. 2005;15:207\u2013222.","journal-title":"Int J Neural Syst"},{"key":"5202159_CR32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0167-9473(99)00114-0","volume":"34","author":"R Orre","year":"2000","unstructured":"Orre R, Lansner A, Bate A, Lindquist M. Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Anal. 2000;34:473\u2013493.","journal-title":"Comput Stat Data Anal"},{"key":"5202159_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","volume":"12","author":"JS Almenoff","year":"2003","unstructured":"Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003. 12:517\u201321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157\u2013166.","journal-title":"Clin Pharmacol Ther"},{"key":"5202159_CR35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MLR.0b013e318179253b","volume":"46","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Cheng H, Delzell E, et al. Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care. 2008;46:969\u2013975.","journal-title":"Med Care"},{"key":"5202159_CR36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Mouchel Du","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u2013190.","journal-title":"Am Stat"},{"key":"5202159_CR37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22:517\u2013523.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR38","first-page":"58","volume":"30","author":"M Kulldorff","year":"2011","unstructured":"Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal Design Methods Appl. 2011;30:58\u201378.","journal-title":"Seq Anal Design Methods Appl"},{"key":"5202159_CR39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/biom.12324","volume":"71","author":"IR Silva","year":"2015","unstructured":"Silva IR, Kulldorff M. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance. Biometrics. 2015;71:851\u2013858.","journal-title":"Biometrics"},{"key":"5202159_CR40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/sim.3780","volume":"29","author":"L Li","year":"2010","unstructured":"Li L, Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med. 2010;29:284\u2013295.","journal-title":"Stat Med"},{"key":"5202159_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/rssc.12076","volume":"64","author":"AJ Cook","year":"2015","unstructured":"Cook AJ, Wellman RD, Nelson JC, Jackson LA, Tiwari RC. Group sequential method for observational data by using generalized estimating equations: application to Vaccine Safety Datalink. J Royal Stat Soc C Appl Stat. 2015;64:319\u2013338.","journal-title":"J Royal Stat Soc C Appl Stat"},{"key":"5202159_CR42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/pds.1128","volume":"14","author":"KA Chan","year":"2005","unstructured":"Chan KA, Hauben M. Signal detection in pharmacovigilance: empirical evaluation of data mining tools. Pharmacoepidemiol Drug Saf. 2005;14:597\u2013579.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4310\/SII.2012.v5.n4.a1","volume":"5","author":"SS Zhao","year":"2012","unstructured":"Zhao SS, Cook A, Jackson L, Nelson N. Statistical performance of group sequential methods for observational post-licensure medical product safety surveillance: a simulation study. Stat Interface. 2012;5:381\u2013390.","journal-title":"Stat Interface"},{"issue":"suppl1","key":"5202159_CR44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/pds.2320","volume":"21","author":"AJ Cook","year":"2012","unstructured":"Cook AJ, Tiwari RC, Wellman RD, et al. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):72\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR45","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/sim.6103","volume":"33","author":"L Huang","year":"2014","unstructured":"Huang L, Zalkikar J, Tiwari R. Likelihood ratio based tests for longitudinal drug safety data. Stat Med. 2014;33:2408\u20132424.","journal-title":"Stat Med"},{"key":"5202159_CR46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0962280211413452","volume":"24","author":"JC Nelson","year":"2015","unstructured":"Nelson JC, Cook AJ, Yu O, Zhao S, Jackson LA, Psaty BM. Methods for observational post-licensure medical product safety surveillance. Stat Methods Med Res. 2015;24:177\u2013193.","journal-title":"Stat Methods Med Res"},{"key":"5202159_CR47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.1107","volume":"14","author":"D Banks","year":"2005","unstructured":"Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf. 2005;14:601\u2013609.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5202159_CR48","unstructured":"Food and Drug Administration. FDA Adverse Event Reporting System (FAERS): latest quarterly data files, October-December 2016. https:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/surveillance\/adversedrugeffects\/ucm082193.htm. Accessed April 2017."},{"key":"5202159_CR49","unstructured":"Food and Drug Administration. Manufacturer and User Facility Device Experience Database (MAUDE). https:\/\/www.fda.gov\/MedicalDevices\/DeviceRegulationandGuidance\/PostmarketRequirements\/ReportingAdverseEvents\/ucm127891.htm. Accessed April 2017."},{"key":"5202159_CR50","unstructured":"Food and Drug Administration. MedSun: Medical Product Safety Network. https:\/\/www.fda.gov\/MedicalDevices\/Safety\/MedSunMedicalProductSafetyNetwork\/default.htm. Accessed April 2017."},{"key":"5202159_CR51","unstructured":"European Commission. EUDAMED: European Database on Medical Devices. http:\/\/ec.europa.eu\/idabc\/en\/document\/2256\/5637.html. Accessed April 2017."},{"key":"5202159_CR52","unstructured":"Goldman S.A., et al., A MedWatch Continuing Education Article. Poster presented at: Center for Drug Evaluation and Research Staff College, Food and Drug Administration. 1996."},{"key":"5202159_CR53","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/amiajnl-2012-000881","volume":"19","author":"T Botsis","year":"2012","unstructured":"Botsis T, Buttolph T, Nguyen MD, Winiecki S, Woo EJ, Ball R. Vaccine adverse event text mining system for extracting features from vaccine safety reports. J Am Med Inform Assoc. 2012;19:1011\u20131018.","journal-title":"J Am Med Inform Assoc"},{"key":"5202159_CR54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40264-015-0305-9","volume":"38","author":"TJ Moore","year":"2015","unstructured":"Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf. 2015;38:601\u2013610.","journal-title":"Drug Saf"},{"key":"5202159_CR55","unstructured":"Heinrich J. Adverse drug events: Substantial problem but magnitude uncertain. Testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate, February 1, 2000."},{"key":"5202159_CR56","unstructured":"Dimbil M, Erdman CB, Dmakas A, Kyle RF. Adverse Drug Event Reporting Rates: Comparing FAERS to Clinical Trials. Paper presented at: AMPC Annual Meeting. 2017."},{"key":"5202159_CR57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2042098613490780","volume":"4","author":"RG Sharrar","year":"2013","unstructured":"Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4:211\u2013219.","journal-title":"Ther Adv Drug Saf"},{"key":"5202159_CR58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1365-2125.2011.04087.x","volume":"72","author":"A Boer de","year":"2011","unstructured":"de Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol. 2011;72:909\u2013911.","journal-title":"Br J Clin Pharmacol"},{"key":"5202159_CR59","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u2013908.","journal-title":"Br J Clin Pharmacol"},{"key":"5202159_CR60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda T, Kadoyama K, Minami K, Okuno Y. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci. 2014;11:461.","journal-title":"Int J Med Sci"},{"key":"5202159_CR61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/clpt.2014.17","volume":"95","author":"H Fang","year":"2014","unstructured":"Fang H, Su Z, Wang Y, et al. Exploring the FDA Adverse event reporting system to generate hypotheses for monitoring of disease characteristics. Clin Pharmacol Ther. 2014;95:496\u2013498.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479017741112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479017741112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479017741112\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479017741112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479017741112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T10:42:33Z","timestamp":1719744153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479017741112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["5202159"],"URL":"https:\/\/doi.org\/10.1177\/2168479017741112","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"21 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}